Abcentra LLC Announces First Patient Dosed in Phase 2b “FORTIFY” Clinical Trial Evaluating Orticumab in Patients with Cardiovascular Disease
LOS ANGELES, August 12, 2025 – Abcentra LLC, a clinical-stage [...]
Abcentra Announces Appointment of Dr. Peter Libby as a Board Member as it Enters Orticumab’s Phase 2b Trial (FORTIFY)
LOS ANGELES, June 24, 2025 /PRNewswire/ -- Abcentra LLC (Abcentra), a [...]
Abcentra Experts to Present at 2024 Imperial Vulnerable Patient & Plaque Meeting
Abcentra is excited to announce our upcoming participation in [...]
Large CT Study Shows Benefits of AI in Predicting CV Risks in Patients Without Obstructive CAD
This article was originally published in Diagnostic Imaging and was written [...]
AI helps cardiologists track new drug’s effect on inflammation
This article was originally published in Cardiovascular Business and [...]
American College of Cardiology Presentation Highlights Orticumab’s Promising Results Showing Potential to Reduce Coronary Inflammation
ATLANTA, April 8, 2024 /PRNewswire/ -- Abcentra LLC, a clinical-stage [...]
Entrepreneur and Cardiologist Michael H. Davidson Appointed to Board of Directors
Los Angeles, California (October 13, 2021) – Abcentra LLC [...]
Abcentra Announces First Patients Dosed with Orticumab in Clinical Trial
FOR IMMEDIATE RELEASE Los Angeles, California (August 04, 2021) [...]
Timothy Wright Joins Board of Directors
Los Angeles, California (August 26, 2020) – Abcentra™ LLC, [...]
CardioVax Announces Name Change to Abcentra
FOR IMMEDIATE RELEASE LOS ANGELES, Jan. 30, 2019 /PRNewswire/ — CardioVax, a [...]
